WG, CRWE, DPO, ENZ, SHP - Stock Highlights From DrStockPick.com!

Dec. 28, 2010 3:08 PM ET

Crown Equity Holdings Inc. (OTCBB:CRWE) announced today that its subsidiary company, Crown Tele Services Inc. is still moving forward after dissolving its joint venture with Communication Expert Corporation and will gradually start rolling out its internet based voice and video service IP-PBX solutions next year.

The cornerstone of Crown Tele Services Inc. strategy is to meet the highest standards when it comes to delivering VoIP (Voice over Internet Protocol) communication solutions specifically designed to meet the market needs.

Hosted IP-PBX is a superior alternative to any others based IP PBX system. It delivers a productive set of business-grade calling features and integrates all your local, long distance and Internet access services over a single network connection. This way, you can take advantage of all the calling features anywhere in the world.

The principle behind VoIP is simple. Calls are placed over the Internet instead of using dedicated voice lines to do the job. This is easy to understand once we realized that all information can be digitized and sent as a signal over a wire. In fact, this also happens with regular voice - your sound signals are encoded and sent over a wire. With the Internet, such things become easy and voice communication can happen in real time just as with a normal phone.

Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing and Web sites, which bring together targeted audiences and advertisers that want to reach them. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

******************************************

Enzo Biochem, Inc. (NYSE:ENZ) is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.

The business activities of Enzo Biochem are performed by the company’s three wholly owned subsidiaries . . . Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs. Such activities include research and development, manufacturing and marketing of biomedical research products and tools through Enzo Life Sciences and research and development of therapeutic products through Enzo Therapeutics and the operation of a regional clinical reference laboratory through Enzo Clinical Labs.

Enzo Biochem, Inc. reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

The Company's financial condition remained strong, with working capital of $42.1 million. As of October 31, 2010, cash and cash equivalents, plus short term investments in US Treasury Bills, totaled $31.6 million. At November 30, 2010 Enzo’s cash, and cash equivalents and short-term investments were $33.9 million, which exceeded the July 31, 2010 balance by $0.3 million. Cash utilization in operations declined year over year by approximately $1 million to $1.8 million principally due to the reduced loss in the 2011 period. Management’s plan is to move towards being cash flow positive from operations in calendar 2011. There was no debt.

******************************************

ShangPharma Corporation America (NYSE:SHP) announced that it will be meeting investors at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco from January 10 to 13, 2011. Michael Hui, founder and Chief Executive Officer of ShangPharma, and Kevin Chen, Chief Operating Officer and Chief Financial Officer, will host a group presentation at 1:30pm (Pacific Time) on January 12, 2011. The presentation materials will be available under the ‘Webcast and Presentation’ section of the Company’s investor relations website.

ShangPharma Corporation, through its subsidiaries, operates as a pharmaceutical and biotechnology research and development outsourcing company. The company provides a range of integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies.

******************************************

Dow 30 Premium Dow 30 Enhanced (NYSE:DPO) announced that two closed-end funds, Dow 30SM Premium & Dividend Income Fund Inc. (NYSE: DPD) and Dow 30SM Enhanced Premium & Income Fund Inc. (NYSE: DPO), will change from paying distributions on a monthly basis to paying on a quarterly basis. There are no other changes to any of the funds’ investment objectives or strategies. In addition, distribution dates and amounts for November 2010 will remain unchanged. Shareholders will receive a regular monthly distribution on December 31, 2010 and thereafter receive distributions on a quarterly basis beginning on April 1, 2011.

******************************************

Willbros Group Inc. (NYSE:WG) announced that a unit of its Utility Transmission & Distribution segment, Hawkeye, LLC, based in Hauppauge, New York, was awarded a contract by Bangor Hydro Electric Company to rebuild Bangor Hydro’s existing 115 kV Line 64 transmission line, which originates in Bangor, Maine and extends north to Chester, Maine, for a total of approximately 44 miles (”Line 64 Project”). The Line 64 Project is comprised of two segments: the Northern Segment, which extends from the Enfield Substation to the Keene Road Substation, for a distance of approximately 12 miles; and the Southern Segment, which extends from the Enfield Substation to the Gorham Substation, for a distance of approximately 32 miles.

Willbros Group, Inc. provides engineering, procurement, and construction services to the oil and gas, refinery, petrochemical, and power industries primarily in the United States, Canada, and Oman. It operates through two segments: Upstream Oil and Gas, and Downstream Oil and Gas.

Disclaimer:Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(Read more athttp://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.